2010
DOI: 10.1021/ml900018m
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of the First Potent and Selective Inhibitor of Centromere-Associated Protein E: GSK923295

Abstract: Inhibition of mitotic kinesins represents a novel approach for the discovery of a new generation of anti-mitotic cancer chemotherapeutics. We report here the discovery of the first potent and selective inhibitor of centromere-associated protein E (CENP-E) 3-chloro-N-{(1S)-2-[(N,N-dimethylglycyl)amino]-1-[(4-{8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl}phenyl)methyl]ethyl}-4-[(1-methylethyl)oxy]benzamide (GSK923295; 1), starting from a high-throughput screening hit, 3-chloro-4-isopropoxybenzoic acid 2. Co… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
56
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 59 publications
(56 citation statements)
references
References 29 publications
(59 reference statements)
0
56
0
Order By: Relevance
“…Such ATP-competitive behavior had been observed during the optimization of this chemical series of CENP-E inhibitors (16). Remarkably, chemical modifications as small as a one carbon extension of a sidechain were sufficient to alter the steady-state mechanism of inhibition from ATP-uncompetitive to ATP-competitive behavior (16). Such minor changes seemed (Table 1, Table S1, and Fig.…”
Section: Resultsmentioning
confidence: 66%
See 2 more Smart Citations
“…Such ATP-competitive behavior had been observed during the optimization of this chemical series of CENP-E inhibitors (16). Remarkably, chemical modifications as small as a one carbon extension of a sidechain were sufficient to alter the steady-state mechanism of inhibition from ATP-uncompetitive to ATP-competitive behavior (16). Such minor changes seemed (Table 1, Table S1, and Fig.…”
Section: Resultsmentioning
confidence: 66%
“…Medicinal chemistry optimization of initial inhibitors gave rise to a series of high affinity, stereoselective, specific and drug-like inhibitors of CENP-E with potent on-target activity against human cancer cells, culminating in the identification of GSK923295 and related compounds ( Fig. 1 and Table S1) (16).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…CENP-E is expressed predominantly in mitosis (and G2) [290] and plays an important role in peripheral chromosome congression [293,295,300], thereby representing an attractive target for cancer therapeutics. GSK923295 is an allosteric inhibitor of CENP-E that blocks its microtubule stimulated ATPase activity and stabilizes the interaction between the motor domain and microtubules [449,450]. GSK923295 has demonstrated both in vitro and in vivo antitumor activity against various malignancies [449,451,452,453,454,455].…”
Section: Targeting Chromosome Congression For Cancer Therapymentioning
confidence: 99%
“…These findings also raise the intriguing possibility that native cellular ligands may exist that bind at this site and regulate kinesins. Another notable point is that this class of CENP-E inhibitors can switch between ATPuncompetitive and ATP-competitive inhibition with chemical modifications as small as a single carbon extension (16).…”
mentioning
confidence: 99%